{"id":"trivalent-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site soreness, redness, or swelling"},{"rate":"1–5","effect":"Fever"},{"rate":"5–10","effect":"Myalgia (muscle aches)"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine contains inactivated (killed) influenza virus particles or antigens from three circulating influenza strains (typically two A strains and one B strain). When administered, it triggers both humoral and cellular immune responses, leading to the production of strain-specific antibodies and memory B cells. Upon exposure to wild-type influenza virus, these pre-existing antibodies neutralize the virus and prevent or reduce the severity of infection.","oneSentence":"The trivalent influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus, providing protection against seasonal flu infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:41.765Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children ≥6 months of age"}]},"trialDetails":[{"nctId":"NCT07493460","phase":"PHASE4","title":"Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-08-26","conditions":"Immunology, Healthy Adults","enrollment":25},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT07291635","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine","status":"RECRUITING","sponsor":"Aramis Biotechnologies Inc.","startDate":"2026-02-25","conditions":"Influenza","enrollment":728},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT07282795","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-03-31","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":670},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT06641180","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-04","conditions":"Influenza","enrollment":1180},{"nctId":"NCT00800605","phase":"PHASE3","title":"Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-12","conditions":"Influenza","enrollment":7250},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT06664151","phase":"EARLY_PHASE1","title":"A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-11-26","conditions":"Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer","enrollment":25},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT04210349","phase":"PHASE3","title":"Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-01-09","conditions":"Influenza","enrollment":7106},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT06507553","phase":"PHASE1","title":"Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-08-12","conditions":"Influenza, Healthy Volunteers","enrollment":400},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT06049927","phase":"PHASE3","title":"A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-09-16","conditions":"Seasonal Influenza","enrollment":3300},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":"COVID-19","enrollment":9320},{"nctId":"NCT05663463","phase":"NA","title":"Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-09-11","conditions":"Solid Organ Transplant","enrollment":74},{"nctId":"NCT06744205","phase":"PHASE1, PHASE2","title":"A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-06","conditions":"Influenza, Healthy Volunteers","enrollment":1162},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT06482359","phase":"PHASE2, PHASE3","title":"Lot Consistency Study of COVID-19 and Influenza Combination Vaccine","status":"WITHDRAWN","sponsor":"Novavax","startDate":"2025-02-01","conditions":"COVID-19, Influenza","enrollment":""},{"nctId":"NCT06485752","phase":"PHASE2, PHASE3","title":"Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine","status":"WITHDRAWN","sponsor":"Novavax","startDate":"2024-11","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04080531","phase":"PHASE4","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-10-18","conditions":"Plasma Cell Neoplasm","enrollment":165},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT06765187","phase":"","title":"Cross-sectional Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Between 18 and 64 Years Old Using the Vaccinees Perception of Injection","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-18","conditions":"Influenza Immunization, Health Volunteers","enrollment":447},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT03179761","phase":"PHASE2","title":"High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2017-10-09","conditions":"Hematopoietic Cell Transplantation","enrollment":124},{"nctId":"NCT03849560","phase":"PHASE2, PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":"Influenza","enrollment":612},{"nctId":"NCT02860039","phase":"PHASE2","title":"High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2016-09","conditions":"Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza","enrollment":170},{"nctId":"NCT01538940","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2011-11-01","conditions":"Influenza","enrollment":415},{"nctId":"NCT02936180","phase":"PHASE4","title":"Standard Versus High Dose Inactivated Influenza Vaccine in RA","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-10","conditions":"Rheumatoid Arthritis","enrollment":279},{"nctId":"NCT00386542","phase":"PHASE1, PHASE2","title":"Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children","status":"COMPLETED","sponsor":"Pedro Moro","startDate":"2006-10","conditions":"Influenza","enrollment":450},{"nctId":"NCT03722589","phase":"PHASE4","title":"Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-09-12","conditions":"Influenza","enrollment":944},{"nctId":"NCT05245552","phase":"PHASE3","title":"A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-08-08","conditions":"Seasonal Influenza","enrollment":217},{"nctId":"NCT00630331","phase":"PHASE3","title":"Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-10","conditions":"Influenza","enrollment":11404},{"nctId":"NCT06385821","phase":"PHASE3","title":"A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2022-09-21","conditions":"Influenza, Influenza A, Influenza, Human","enrollment":824},{"nctId":"NCT06286488","phase":"PHASE4","title":"Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2020-09-15","conditions":"Influenza, Obesity, Pregnancy; Infection","enrollment":1500},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT06252051","phase":"PHASE4","title":"Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-01-05","conditions":"Influenza, Vaccine Reaction, Diabetes Mellitus","enrollment":76},{"nctId":"NCT03744104","phase":"PHASE3","title":"A Clinical Trial of A Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-10-11","conditions":"Influenza","enrollment":2688},{"nctId":"NCT04363359","phase":"PHASE2","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-01-15","conditions":"Influenza","enrollment":1980},{"nctId":"NCT02529904","phase":"PHASE2","title":"ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Influenza","enrollment":120},{"nctId":"NCT02385123","phase":"PHASE4","title":"Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-04-01","conditions":"Influenza, Influenza Immunisation","enrollment":60},{"nctId":"NCT02485639","phase":"PHASE4","title":"Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-23","conditions":"Influenza, Influenza Immunisation","enrollment":27},{"nctId":"NCT00566345","phase":"PHASE3","title":"Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-11","conditions":"Influenza","enrollment":3670},{"nctId":"NCT02677493","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-10","conditions":"Influenza","enrollment":1794},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT04484532","phase":"EARLY_PHASE1","title":"Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-10-17","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":130},{"nctId":"NCT01344057","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza","enrollment":63},{"nctId":"NCT02134184","phase":"PHASE4","title":"The Influence of Chronic CMV Infection on Influenza Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-10","conditions":"Cytomegalovirus Infections, Influenza","enrollment":78},{"nctId":"NCT03669627","phase":"PHASE2","title":"CT18 Infant Influenza Priming Study in Vaccine Naive Infants","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-11-01","conditions":"Influenza","enrollment":159},{"nctId":"NCT01964989","phase":"PHASE3","title":"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-11","conditions":"Influenza Virus","enrollment":10644},{"nctId":"NCT02882100","phase":"PHASE4","title":"Adjuvanted Influenza Vaccination in U.S. Nursing Homes","status":"COMPLETED","sponsor":"Insight Therapeutics, LLC","startDate":"2016-04","conditions":"Influenza, Influenza-like Illness","enrollment":823},{"nctId":"NCT03293498","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)","status":"COMPLETED","sponsor":"Novavax","startDate":"2017-09-18","conditions":"Influenza","enrollment":330},{"nctId":"NCT02523287","phase":"PHASE4","title":"Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-10-02","conditions":"Safety Markers of Adjuvanted Influenza Vaccine","enrollment":240},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375},{"nctId":"NCT03438487","phase":"","title":"Flucelvax (TIVc or QIVc) Pregnancy Registry","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-09-01","conditions":"Influenza, Human, Pregnancy, Birth Defect","enrollment":692},{"nctId":"NCT01676402","phase":"PHASE1","title":"Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-08","conditions":"Influenza","enrollment":316},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT01808456","phase":"PHASE4","title":"Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.","status":"COMPLETED","sponsor":"Inova Health Care Services","startDate":"2013-10","conditions":"Influenza, Human, Transplantation Infection","enrollment":62},{"nctId":"NCT03704740","phase":"PHASE3","title":"Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2018-10-25","conditions":"Influenza","enrollment":676},{"nctId":"NCT03344029","phase":"PHASE4","title":"Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-11-03","conditions":"Influenza, Flu","enrollment":1600},{"nctId":"NCT03282240","phase":"PHASE3","title":"Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-09-08","conditions":"Influenza","enrollment":2670},{"nctId":"NCT04833101","phase":"PHASE4","title":"Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-04-07","conditions":"COVID-19","enrollment":120},{"nctId":"NCT00539981","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09-15","conditions":"Influenza","enrollment":4648},{"nctId":"NCT02550197","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":300},{"nctId":"NCT02787044","phase":"PHASE4","title":"INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-08-01","conditions":"Heart Failure, Myocardial Infarction","enrollment":5388},{"nctId":"NCT03068949","phase":"PHASE4","title":"Comparison of Three Licensed Influenza Vaccines","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2015-10-28","conditions":"Influenza","enrollment":413},{"nctId":"NCT05070494","phase":"PHASE4","title":"Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-03-01","conditions":"ESRD, Influenza Vaccine, Seroprotection","enrollment":175},{"nctId":"NCT02747407","phase":"","title":"Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-05","conditions":"Astrocytoma, Glioma, Oligodendroglioma","enrollment":55},{"nctId":"NCT00461981","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Immune Responses of FluMist®","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2007-05","conditions":"Influenza Vaccine","enrollment":101},{"nctId":"NCT00192192","phase":"PHASE3","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2000-11","conditions":"Influenza","enrollment":20},{"nctId":"NCT00192231","phase":"PHASE3","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-04","conditions":"Influenza","enrollment":120},{"nctId":"NCT00128167","phase":"PHASE3","title":"Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2004-10","conditions":"Influenza","enrollment":8500},{"nctId":"NCT00192348","phase":"PHASE1","title":"A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-05","conditions":"Healthy","enrollment":120},{"nctId":"NCT00987350","phase":"PHASE4","title":"Safety Study of Seasonal Influenza Vaccine by Jet Injection","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-01","conditions":"Healthy Adults","enrollment":60},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT00841763","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Pandemic Influenza Disease","enrollment":3647},{"nctId":"NCT01863849","phase":"PHASE4","title":"Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2013-08-22","conditions":"Influenza Prophylaxis","enrollment":120},{"nctId":"NCT02387294","phase":"PHASE3","title":"Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2014-10","conditions":"Human Influenza","enrollment":120},{"nctId":"NCT02933723","phase":"NA","title":"Immunogenicity of Influenza Vaccine in Long Term Care","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2016-10","conditions":"Influenza","enrollment":200},{"nctId":"NCT03448705","phase":"PHASE1","title":"Safety of 4Fluart ID Suspension for Injection in Adult Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2018-01-31","conditions":"Human Influenza","enrollment":36},{"nctId":"NCT00283283","phase":"PHASE2","title":"Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-11","conditions":"Influenza","enrollment":1316},{"nctId":"NCT03699839","phase":"PHASE2, PHASE3","title":"Reducing the Burden of Influenza After Solid-Organ Transplantation","status":"COMPLETED","sponsor":"Oriol Manuel","startDate":"2018-10-26","conditions":"Influenza, Organ Transplantation","enrollment":619},{"nctId":"NCT00929331","phase":"PHASE3","title":"Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-11","conditions":"Influenza, Human","enrollment":110},{"nctId":"NCT01157702","phase":"PHASE3","title":"Yearly Strain Variation Study, 2010/2011","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2010-07","conditions":"Influenza, Seasonal Influenza","enrollment":110},{"nctId":"NCT01422200","phase":"PHASE4","title":"Flu Vaccine Study in Neuromuscular Patients 2011","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2011-08","conditions":"Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Congenital Muscular Dystrophy","enrollment":22},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT03314662","phase":"PHASE3","title":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-10-17","conditions":"Influenza, Human","enrollment":1778},{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503},{"nctId":"NCT04355806","phase":"","title":"Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-06-01","conditions":"Non Small Cell Lung Cancer, Influenza Vaccine","enrollment":160},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT02894840","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-11","conditions":"Influenza","enrollment":340},{"nctId":"NCT01561989","phase":"NA","title":"Cholecalciferol and Flu Vaccine in Treating Healthy Participants","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2011-10","conditions":"Healthy, no Evidence of Disease","enrollment":11},{"nctId":"NCT02972957","phase":"PHASE4","title":"A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-01-30","conditions":"Influenza","enrollment":364},{"nctId":"NCT03293732","phase":"PHASE1","title":"Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults","status":"COMPLETED","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2012-11-28","conditions":"Flu, Human","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":682,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Flu shot","Flu vaccination","Fluzone","Fluzone HD","Fluzone High-dose"],"phase":"marketed","status":"active","brandName":"Trivalent Influenza Vaccine","genericName":"Trivalent Influenza Vaccine","companyName":"MedImmune LLC","companyId":"medimmune-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"The trivalent influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus, providing protection against seasonal flu infection. Used for Seasonal influenza prevention in adults and children ≥6 months of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}